UK Stocks-Factors to watch on November 16
UK Stocks-Factors to watch on November 16 Nov 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening flat on Monday, with futuresFFIc1 at 0.0%.
* ASTRAZENECA: AstraZeneca AZN.L has cut about 600 jobs from its respiratory and immunology commercial teams in the US as part of its three-year cost-savings initiative, Bloomberg News reported on Friday, citing people familiar with the matter.
* PROPERTY: Asking prices for British homes marketed in the four weeks to November 7 fell by more than usual for the time of year.
* SHELL: Shell Egypt SHEL.L has started production from the Mina West gas field in the Egyptian Mediterranean, the company said on Sunday, adding a new source of domestic supply.
* CANACCORD GENUITY: Canaccord Genuity CF.TO agreed to sell its British wealth management business at an enterprise value of about £1.17 billion ($1.55 billion), the company said on Sunday.
* BREXIT: British Prime Minister Andy Burnham is set on Monday to say he wants to have a difficult conversation about the "obvious truth" of the costs of Brexit in order to reset Britain's relationship with the European Union ahead of a summit in Brussels this week.
* JOBS: The British government announced on Saturday that it would expand a programme to provide guaranteed jobs to young people.
* COMMODITIES: Oil prices fell on Monday, gold held steady after hitting a more-than-one-year low last week, London copper prices fell for a third straight session.
* FTSE: The UK blue-chip index .FTSE closed up 0.4%, at three-month highs on Friday, lifted by energy and consumer stocks, as a wobble in the global AI trade pushed investor towards defensive sectors.
* UK CORPORATE DIARY:
Ninety One | N91.L | Q3 trading update |
Big Yellow Group | BYG.L | Interim results |
Legal & General | LGEN.L | Interim results |
Grafton Group | GFTU_u.L | Q3 trading update |
* For more on the factors affecting European stocks, please click on: LIVE/
TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB
(Compiled by Ankita Bora in Bengaluru)
((Ankita.Bora@thomsonreuters.com))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)